title: Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
abstract: We have previously reported on phase I/II studies of irinotecan plus S-1 therapy for advanced gastric cancer. Based on the safety and efficacy data that were obtained, this phase II study was planned to assess the efficacy of irinotecan plus S-1 for patients with advanced colorectral cancer. A total of 40 patients are enrolled at 13 medical institutions. The objective of this study was to establish a useful chemotherapy regimen for an out-patient setting.
authors.affiliation: Department of Gastroenterology, Hokkaido University School of Medicine, North 15, West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan. ykomatsu@med.hokudai.ac.jp.
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Komatsu
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yuuki
authors.forename: Nozomu
authors.initials: N
authors.lastname: Fuse
authors.forename: Masaaki
authors.initials: M
authors.lastname: Takei
authors.forename: Takashi
authors.initials: T
authors.lastname: Kato
authors.forename: Takuto
authors.initials: T
authors.lastname: Miyagishima
authors.forename: Mineo
authors.initials: M
authors.lastname: Kudo
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Kunieda
authors.forename: Miki
authors.initials: M
authors.lastname: Tateyama
authors.forename: Osamu
authors.initials: O
authors.lastname: Wakahama
authors.forename: Takashi
authors.initials: T
authors.lastname: Meguro
authors.forename: Hiroko
authors.initials: H
authors.lastname: Ohizumi
authors.forename: Maso
authors.initials: M
authors.lastname: Watanabe
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Akita
authors.forename: Yu
authors.initials: Y
authors.lastname: Sakata
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin